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b Université de Strasbourg, Inserm, UMR-S1118, Strasbourg, FranceIn this article of EBioMedicine, VivianaMoresi and colleagues provide a conditional allele of Hdac4, they ablated HDAC4 in muscle through
genetic evidence that skeletalmuscle HDAC4 exerts a protective role for
neuromuscular junction and muscle innervation in amyotrophic lateral
sclerosis (ALS) [1].
HDACs are enzymes able to remodel the chromatin through histone
deacetylation. The hypothesis that alterations in chromatin remodeling
participates in ALS progression comes from studies published 10 years
ago showing that ALS disease progression in amousemodel is associated
with a loss of the histone acetyl transferase CBP and decreased
histone acetylation in motor neurons at disease onset [2]. However,
counteracting pharmacologically decreased histone acetylation by
broad HDAC inhibition had a moderate effect on whole animal survival
[3,4]. More particularly, such treatment efﬁciently protected motor neu-
ron cell bodies, and slightly delayed the onset of motor decline, but was
unable to prevent disruption of neuromuscular junctions [5]. It is there-
fore likely that HDAC inhibitors might negatively inﬂuence other cell
types involved in ALS. Pigna and collaborators show here that muscle
HDAC4 is a strong candidate for thesenegative effects ofHDAC inhibition.
HDAC4 is a member of the class IIa family that is devoid of
deacetylase activity, and likely leads to histone desacetylation through
binding of Class I HDACs [6]. In neurons, HDAC4 is predominantly cyto-
plasmic, particularly concentrated indendritic spines [7]. Speciﬁcneuro-
nal loss of HDAC4 leads to defects in motor coordination, learning and
anxietydisorder [8].HDAC4 is also expressed inmuscle, andhas a critical
developmental role through inhibition of the transcriptional activity of
MEF2 [9]. HDAC4 is highly upregulated upon denervation, as occurs in
ALS, and is enriched at neuromuscular junctions where it activates the
subsynaptic gene expression program [10,11]. Muscle speciﬁc deletion
of HDAC4 thus leads to defective induction of subsynaptic gene expres-
sion but without impactingmusclemass [12,13]. Surprisingly, suchma-
nipulation also leads tobettermuscle reinnervation after nerve injury, in
part through relieving the expression of FGF-related retrograde signals
to motor neurons [14]. In patients, high muscle HDAC4 expression was
correlated to faster disease progression [15]. Given the broad roles of
HDAC4 in the different cell-types, it was difﬁcult to predict whether
HDAC4 loss would be beneﬁcial or deleterious in ALS.
Pigna and collaborators here used an elegant genetic strategy to
dissect the role of HDAC4 in muscle in a mouse model of ALS. UsingDOI of original article: https://doi.org/10.1016/j.ebiom.2019.01.038.
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moter, and introduced a transgene allowing expression of mutant
SOD1, a cause of familial ALS. They observed that muscle HDAC4
deletion exacerbates a number of disease parameters in this model:
acceleration of weight loss, muscle atrophy and weakness leading to
acceleration of disease onset although overall survival remained unaf-
fected. Consistent with a critical role of HDAC4 in neuromuscular junc-
tion, muscle HDAC4 ablation led to smaller and more frequently
denervated neuromuscular synapses in mutant SOD1 mice, and po-
tently blunted the induction of the so-called denervation response
mounted by muscle in response to inactivity. Notably, no effect was
observed on motor neuron survival. Muscle proteolytic pathways
were also less activated in ALS mice without muscle HDAC4. Interest-
ingly, HDAC4 ablation led to transcriptional dysregulations related to
metabolism, ubiquitin-dependent catabolism and skeletal muscle re-
sponse to denervation, including the upregulation of mitochondrial
uncoupling protein 1, whose muscle expression is sufﬁcient to recapit-
ulate most of the observed effects in these animals [16]. As an overall
conclusion of the study, Pigna and collaborators demonstrate that the
pathways activated by HDAC4 in muscle during ALS are responsible
for compensatory reinnervation through the myogenin pathway. Abla-
tion of this key player in the pathway blunts this response and nega-
tively affects NMJ response to denervation, while potentially inducing
hypermetabolism.
The study by Pigna and collaborators provides an elegant demon-
stration why class IIa HDAC inhibition may not be suitable to protect
the neuromuscular function in ALS, consistent with a recent study that
showed only a transient protection of motor performance after treat-
ment of the same ALS model with the class II speciﬁc HDAC inhibitor
MC1568 [17]. The current study also nicely conﬁrms 10 years old stud-
ies using the pan-HDAC inhibitor valproic acid that potently protected
motor neurons, likely via class I HDACs inhibition-dependent effects,
but did not prevent NMJ denervation at late stages, possibly because
of class IIaHDACs inhibition-dependent effects. In the context of ALS, re-
cent work has shown that HDAC6 inhibitors could provide interesting
protection in various mouse models [18] and inhibitors of class I
HDACs remain also interesting targets for neuronal protection, espe-
cially as HDAC1 appears as a downstream target of both FUS and TDP-
43 related ALS. Future work in this area should focus on increasing
selectivity of HDAC inhibitors, and ameliorate targeting of the CNS to
avoid the deleterious effects of HDAC inhibition in the periphery.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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